News AbbVie and J&J claim new Imbruvica okay in US AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL) to be approved by the FDA, its tenth indication.
News Roche's Mabthera faces cut-price competition in EU Blockbuster likely to face cheap near-copy for first time.
News AbbVie's Venclyxto approved in Europe in CLL AbbVie blood cancer drug tipped to be a blockbuster.
News NICE rejects Roche drug in follicular lymphoma NICE uncertain over survival data for Gazyvaro and bendamustine.
News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends